Los Angeles Capital Management LLC Has $2.97 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Los Angeles Capital Management LLC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 83.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,490 shares of the biotechnology company’s stock after purchasing an additional 67,740 shares during the quarter. Los Angeles Capital Management LLC owned 0.06% of ADMA Biologics worth $2,968,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ADMA. Assenagon Asset Management S.A. lifted its stake in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares in the last quarter. Seven Eight Capital LP bought a new stake in ADMA Biologics in the 2nd quarter valued at $1,992,000. Louisiana State Employees Retirement System acquired a new position in ADMA Biologics in the 3rd quarter worth $2,253,000. Point72 Asset Management L.P. bought a new position in ADMA Biologics during the 2nd quarter worth about $1,157,000. Finally, New York State Teachers Retirement System acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $1,821,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 3.1 %

ADMA stock opened at $21.78 on Wednesday. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The company has a market cap of $5.08 billion, a price-to-earnings ratio of 77.79 and a beta of 0.64. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The business has a 50 day moving average price of $18.22 and a two-hundred day moving average price of $14.06.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 59.29%. During the same period in the previous year, the company earned $0.01 earnings per share. Analysts anticipate that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of research reports. HC Wainwright increased their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James lifted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th.

Insider Activity

In related news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is owned by company insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.